Community News

LOS ANGELES--(BUSINESS WIRE)-- #VaccinateOurWorld--AHF Supports WTO Chief's Call to End Vax Apartheid

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside (NR) healthy aging nutrient. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex provides its patented NR ingredient, Niagen®, technological and scientific expertise to research institutions and universities at no cost. ChromaDex continues […]

RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (the “Company,” “PURE” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2021. Q3: Summary of Results of Operations Net product sales for the fiscal third quarter ended April 30, 2021 decreased 75% to $556,000, compared to $2,221,000 for the fiscal third quarter […]

TORRANCE, Calif.--(BUSINESS WIRE)-- #5S--California Manufacturing Technology Consulting® (CMTC) recently delivered Lean Training to RKL Technologies, Inc. (“RKL”) employees to help organize RKL’s shop floor and improve their manufacturing processes. RKL Technologies was founded in 1983 to provide contract machine shop services to the medical device industry. The company has since expanded to serve major multinational corporations, as well as smaller local businesses, in the aerospace, […]

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for

LOS ANGELES--(BUSINESS WIRE)--MedTech Innovator unveils top 50 medtech startups selected for annual Showcase and Accelerator.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has received FDA authorization to conduct a Phase 1b/2 open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva (N-803, an IL-15 superagonist) and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy (sacituzumab govitecan-hziy), in subjects with advanced triple-negative breast

ALISO VIEJO, Calif.--(BUSINESS WIRE)--BrainChip CEO Shares Business Insights with Investment Community at the OTC Market Group’s International Virtual Investor Conference

SAN DIEGO, Calif. & LOS ANGELES & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #diversity--Biocom California Establishes DE&I Member Pledge to Ignite Lasting Change in Life Sciences

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #INDstatus--PharmaCyte to hold virtual shareholder meeting to vote on critical propositions and update shareholders on FDA required work to lift clinical hold.

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta® (axicabtagene ciloleucel) – the first and only CAR T-cell therapy approved in patients with relapsed or refractory indolent follicular lymphoma (FL). At a minimum follow-up of 18 months, 94% of patients had achieved a response, and secondary endpoints of median progression-free survival (PFS) and overall survival (OS) were not yet reached. […]

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced its HIV clinical pipeline with an HIV cure study using Anktiva™ (N-803), which is now enrolling participants in the U.S. The trial will study whether Anktiva can control HIV alone or together with combination broadly neutralizing antibodies (bNABs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored. The study is sponsored by […]

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and othe

TUSTIN, Calif.--(BUSINESS WIRE)--Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ Engine (AiCE), Canon Medical Systems USA Inc.’s Deep Learning Reconstruction (DLR) technology, is now 510(k) cleared on the Cartesion Prime Digital PET/CT system and will be showcased at SNMMI 2021 for both PET and CT acquisitions. The Cartesion Prime with AiCE can help clinicians produce high-quality images consistently and routinely, paving the way for […]

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomization in its U.S. Food and Drug Administration (FDA) New Drug Application (NDA) Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant. The iDose TR Phase 3 clinical program consi

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- #3DP--Desktop Health announces CE Mark for Flexcera resin, paving the way for the international launch of the next generation 3D printed dentures.

LOS ANGELES--(BUSINESS WIRE)---- $curr #NicoleKidman--Nicole Kidman and Sera Labs Inc., a CURE Pharmaceutical Company, launch clean, plant-based beauty line Seratopical Revolution, and new ad campaign.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the Therapeutic Goods Administration (TGA) of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure (IOP) in eyes of patients with primary open-angle glaucoma where IOP remains un

LOS ANGELES--(BUSINESS WIRE)--Kilroy Realty Corporation (NYSE: KRC) today announced that following its successful leasing of Kilroy Oyster Point Phase 1, it started construction on the second phase of its five phase, 50-acre, three million square-foot development project in South San Francisco, the West Coast’s largest and most dynamic community of life science companies and research institutions. Kilroy Oyster Point Phase 2 (“KOP 2”) will include approximately 860,000 square feet in […]

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Announces $200 Million of Financing